NEULANDLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses02Member NEULANDLAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member NEULANDLAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NEULANDLAB 2019-04-01 2020-03-31 2020-05-14 INR Lakhs Yearly Single segment Manufacturing of Active Pharmaceuticals Ingredients 2020-01-01 2020-03-31 Audited Consolidated 1916419000.00 17762000.00 1934181000.00 889859000.00 0.00 -29072000.00 329995000.00 70695000.00 76260000.00 424464000.00 1762201000.00 171980000.00 0.00 171980000.00 -83324000.00 348261000.00 264937000.00 0.00 -92957000.00 0.00 0.00 0.00 0.00 -92957000.00 3507000.00 -89450000.00 0.00 0.00 129005000.00 10 -7.25 -7.25 0.00 0.00 -7.25 -7.25 1. The financial results for the quarter and year ended 31st March 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 22nd May 2020. n2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. n3. The Consolidated Financial Results include results of the following wholly owned subsidiaries: n(a) Neuland Laboratories Inc., USA; n(b) Neuland Laboratories KK., Japan. n4. The operations of the Company and its subsidiaries are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments. n5. Effective April 1, 2019, the Company has adopted Ind AS 116 Leases on all lease contracts existing on April 1, 2019 using the modified retrospective method and has taken the cumulative adjustment to retained earnings, on the date of initial application. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs 237.50 Lakhs and a lease liability of Rs. 255.21 Lakhs. The cumulative effect of applying the standard resulted in Rs 17.71 Lakhs being debited to retained earnings, net of taxes. The effect of this adoption did not have a material impact on the results for the quarter and year ended March 31, 2020. n6. Due to COVID-19 situation, there have been several restrictions imposed by the Governments across the globe on the travel, goods movement and transportation considering public health and safety measures during March, 2020. The Group is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The Group has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, inventory, based on the information available to date, both internal and external, while preparing the its financial results as of and for the year ended 31st March, 2020. Based on the assessment done by the management of the Company, there is no significant/material impact of COVID-19 on the results for the quarter and year ended March 31, 2020. n7. The Company has elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Deferred Tax Liabilities (net) and the estimate of Tax Expense for the quarter and year ended March 31, 2020 have been re-measured. Consequent to such revision, there was a one-time charge of Rs. Rs 2,324.66 Lakhs to the Company's Tax Expense. n8. The figures for the quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between the audited figures in respect of the full financial year and the published figures upto nine months of the relevant financial year. n9. The EPS for quarters has not been annualised. n10. The previous quarter's/year's figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/period. n11. The aforesaid Financial Results will be uploaded on the Company's website www.neulandlabs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. Single segment 2019-04-01 2020-03-31 Audited Consolidated 7627108000.00 38859000.00 7665967000.00 3913559000.00 0.00 -111575000.00 1235552000.00 215735000.00 312801000.00 1570670000.00 7136742000.00 529225000.00 0.00 529225000.00 963000.00 366157000.00 367120000.00 0.00 162105000.00 0.00 0.00 0.00 0.00 162105000.00 -4340000.00 157765000.00 0.00 0.00 129005000.00 10 0.00 12.63 12.63 0.00 0.00 12.63 12.63 Manufacturing Expenses 283463000.00 Other Expenses 141001000.00 Manufacturing Expenses 975963000.00 Other Expenses 594707000.00